Date
Wednesday,
24 November 2021
11am-12pm (AEDT)
Location
Zoom Webinar
Register for Link
APR.Intern has partnered with MTPConnect‘s REDI program to offer medtech, biotech & pharma companies a $10,000 subsidy off the cost of engaging a PhD student intern over 3-6 months.
Join us to learn more about APR.Intern, the MTPConnect subsidy, and how your business can benefit from an industry-university collaboration.
This informative session will cover:
Who should attend?
Jarrod Belcher is the Director of MTPConnect’s REDI program, based in Melbourne. Previously, Jarrod was General Manager – Middle East North Africa for Site Group International, an ASX listed company providing Australian accredited and non-accredited training programs around the world. Throughout his career, he has been a passionate workforce development professional committed to assisting companies and industries achieve their potential through skilling workforces, across the Pacific, Asia and Middle East to government, NGO and corporate clients utilising innovative practices to embed and apply newly developed skills and behaviours.
He has led the delivery of the first vocational Bachelor of Biotechnology program delivered in TAFE and the delivery of biotechnology qualifications into China. Jarrod has a background in the biosciences with a BSc in Biochemistry and Molecular Biology from the University of Melbourne, and postgraduate qualifications in training and education and competitive manufacturing.
Glenn is a founder and the Chief Medical Officer for Genepath. He has cross-disciplinary expertise as a paediatric emergency specialist, a molecular geneticist, and an entrepreneur. With over 15 years experience in the public health sector, his strength is driving health system-wide uptake of innovative medical technology.
SUE KWEON
PhD Candidate, UNSW and Former PhD Intern, Genepath
Sue is currently a PhD scholar based at the School of Optometry & Vision Science (SOVS), UNSW. Her multidisciplinary research focuses on understanding how varying levels of hormones can have noticeable effect on the dry eye disease, involving meibomian gland dysfunction.
Earlier this year, Sue completed a three-month industry internship at medtech startup, Genepath, where she applied research expertise to commercial R&D.
Michael has a 20 year professional career assisting innovative technology companies to access government funding, with experience in government, Big 4 management consulting and boutique advisory. He has wide industry exposure in technical areas including a broad spectrum of engineering disciplines, software development, construction, logistics, manufacturing, energy and national resources, agribusiness and the biotech sector.
Michael is passionate about working with scientists and engineers to access funds and resources to progress their R&D and thrives on the challenge of quickly coming to grips with unfamiliar concepts to solve challenging interdisciplinary problems.